Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly binds to the active site of FXa, and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin. Apixaban is approved in...
We hypothesized that viral kinetic modeling could be helpful to prioritize rational drug combinations for COVID‐19. The aim of this research was to use a viral cell cycle model of SARS‐CoV‐2 to explore the potential impact of drugs, or combinations...
Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) the aim is to direct the patient’s own immune system to fight cancer. After remarkable successes of...
In this case study, we look at the drug development journey of Nurtec ODT and how Certara's clin pharm services helped Biohaven achieve FDA approval.
Certara’s contributions have supported >250 drug label claims. Our customers have received >90% of all novel drug approvals by the FDA from 2014 to 2024.
By Yuancheng Chen, Research Associate of Phase 1 Unit, Huashan Hospital, Fudan University, and visiting scholar of Uppsala University Certara recently held its first virtual Phoenix User Group meeting in China. Over this three-day meeting, attendees learned from Certara’s experts...
Our medical affairs consulting services ensure compliance, streamline timelines, and reduce internal burdens. Contact our medical communications experts today!
© 2025 Certara. All Rights Reserved. | Legal | Privacy policy
